On November 13, 2025, the US Food and Drug Administration (FDA) approved the menin inhibitor ziftomenib for adult patients with…

On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved the menin inhibitor revumenib for the treatment of…

On October 23, 2025, the U.S. Food and Drug Administration (FDA) approved belantamab mafodotin, a BCMA-directed antibody and microtubule inhibitor…

VJHemOnc is thrilled to bring you a feature article delving into the field of paroxysmal nocturnal hemoglobinuria (PNH).

On August 29, 2025, the U.S. Food and Drug Administration (FDA) approved rilzabrutinib, an oral Bruton’s tyrosine kinase inhibitor (BTKi),…

VJHemOnc is pleased to share a feature article that explores the latest updates in Richter’s transformation.

VJHemOnc is pleased to share a feature article that explores the growing value of bispecific antibodies in the treatment of…

On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted approval to linvoseltamab, a B-cell maturation antigen (BCMA)…